Kymera Investor Day Presentation Deck
STAT3 Degraders Have Applicability in Serious Inflammatory
and Fibrotic Diseases
Systemic Sclerosis
(SSc)
Idiopathic
Pulmonary Fibrosis
(IPF)
Atopic Dermatitis
(AD) moderate-to-
severe
Rheumatoid
Arthritis (RA)
Patient Impact¹
~85k US
~200K ROW*
per year
~80k US
~180k ROW*
per year
~12m
~60m ROW*
per year
~2m US
~17m ROW*
per year
*EU, UK, Japan, China
KYMERA ©2021 KYMERA THERAPEUTICS, INC.
Fibrosis / Interstitial Lung Disease
Autoimmune
Increased STAT3 and pSTAT3 observed in SSc skin and lung biopsies
• Aberrant IL6/JAK/STAT3 gene signature in biopsies from SSc patients
Tocilizumab no effect on mRSS but change from baseline in FVC at
week 48 (observed FVC and %pFVC) in patients with SSC/ILD
●
●
●
●
STAT3 dependent cytokines (e.g. IL-11) upregulated in lung of IPF
patients and are associated with disease severity
IL-6/gp130 stimulation is mitogenic for IPF fibroblasts but no normal
fibroblasts
SoC reduces the annual rate of FVC decline
STAT3 GoF pat ts exhibits signs of dermatitis
TSLP receptor activates STAT3
Pruritis is linked to mechanical and IL-31R activation of STAT3
Fibrotic changes associated with AD is associated with STAT3 activation
STAT3 mRNA and pSTAT3 are significantly higher in blood of RA patients
STAT3 target genes (BCL3, SOCS3 and PIM1) are upregulated in early RA
Constitutive STAT3 phosphorylation in circulating CD4+ T cells correlates to
IL-6 levels in recent-onset RA
~30% of SoC therapies in moderate to severe RA achieve ACR70 at week 52
¹Bionest
KYMERA R&D DAY - December 16th, 2021
PAGE 69View entire presentation